Te Ahumairangi Investment Management Ltd trimmed its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 12.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,170 shares of the company's stock after selling 5,967 shares during the period. DaVita accounts for approximately 1.3% of Te Ahumairangi Investment Management Ltd's holdings, making the stock its 23rd largest holding. Te Ahumairangi Investment Management Ltd owned approximately 0.05% of DaVita worth $6,307,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of DVA. Franklin Resources Inc. increased its holdings in shares of DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after purchasing an additional 31,502 shares in the last quarter. FMR LLC increased its stake in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company's stock valued at $29,082,000 after buying an additional 154,061 shares during the period. Assenagon Asset Management S.A. raised its position in shares of DaVita by 201.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock worth $11,159,000 after acquiring an additional 49,885 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of DaVita during the third quarter valued at $726,000. Finally, Hussman Strategic Advisors Inc. boosted its holdings in DaVita by 200.0% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock valued at $3,769,000 after acquiring an additional 16,800 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.
DaVita Trading Down 2.8 %
Shares of NYSE DVA traded down $4.37 during midday trading on Friday, reaching $149.37. 1,009,511 shares of the stock were exchanged, compared to its average volume of 810,838. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The business has a 50-day simple moving average of $156.16 and a two-hundred day simple moving average of $157.39. The company has a market capitalization of $11.95 billion, a price-to-earnings ratio of 13.91, a P/E/G ratio of 1.07 and a beta of 1.04.
DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.
Analysts Set New Price Targets
A number of research analysts have issued reports on the stock. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays increased their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Finally, StockNews.com downgraded DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $166.33.
Check Out Our Latest Research Report on DVA
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
